Oncology Corporate Profile
Mirati Therapeutics is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Our compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Our clinical development programs are focused on treating selected tumor types that express high levels of these targets in order to most effectively address unmet patient needs. Our lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. We are also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor and MGCD516, a kinase inhibitor with a distinct target profile.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|mocetinostat||HDAC inhibitor||Bladder cancer||II|
|mocetinostat||HDAC inhibitor||Diffuse large B-cell Lymphoma (DLBCL)||II|
|mocetinostat||HDAC inhibitor||Myelodysplastic Syndrome (MDS)||II|
|MGCD265||multiple tyrosine kinase inhibitor||Head & Neck cancer||I|
|MGCD265||multiple tyrosine kinase inhibitor||Non Small Cell Lung Cancer (NSCLC)||I|
|MGCD516||multiple tyrosine kinase inhibitor||Various cancer types||I|
|mocetinostat (+ MEDI4736)||HDAC inhibitor||Various cancer types||I||Medimmune|
View additional information on product candidates here »
3/27/2017 08:00 pm
3/15/2017 05:00 pm
3/9/2017 11:04 pm
3/9/2017 11:04 pm
3/9/2017 09:02 pm
3/9/2017 09:00 pm
[PR Newswire] - SAN DIEGO, March 9, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) ("the Company," "we," "our," "us," or "Mirati") today reported financial ...
2/13/2017 09:00 pm
[PR Newswire] - SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D, Ph.D., President and CEO of Mirati, will provide a corporate overview during ...
2/1/2017 09:00 pm
2/1/2017 05:02 pm
1/17/2017 03:05 pm
1/9/2017 08:05 pm
1/8/2017 12:03 pm
1/6/2017 10:01 pm
1/6/2017 12:05 pm
[at noodls] - January 6, 2017 SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,350,176 shares of its common stock at ...
1/6/2017 12:03 pm
[PR Newswire] - SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 4,350,176 shares of its common stock at a price to the public of $5.60 per share. In addition, and in lieu of common stock, Mirati is offering to funds affiliated with Boxer Capital, LLC pre-funded warrants to purchase up to an aggregate of 7,258,263 shares of common stock at a purchase price of $5.599 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from this offering are expected to be approximately $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an additional 652,526 shares of common stock in connection with the public offering.
1/5/2017 09:05 pm
[at noodls] - January 5, 2017 Glesatinib demonstrates improved tolerability with new spray dried dispersion formulation; Promising clinical activity observed in NSCLC patients with MET mutations; Early clinical responses ...
1/5/2017 09:05 pm
[at noodls] - January 5, 2017 SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its ...